InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,774.59
(
1.41%
)
Post# of 514
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Roland Rick Perry

Send PM Follow Ignore
Followers 15
Posts 571
Boards Moderated 1
Alias Born 08/04/2011

Roland Rick Perry

Re: None

Monday, 05/29/2017 11:19:53 AM

Monday, May 29, 2017 11:19:53 AM

Post# of 514
Cowen target $15.

Cowen initiates coverage on Immunomedics (NASDAQ: IMMU) with a Outperform rating and a price target of $15.00.

Analyst Dr. Phil Nadeau comments "Immunomedics' lead candidate IMMU-132 has produced compelling Ph. II data in
the treatment of relapsed/refractory mTNBC and our physician consultants expect IMMU-132 to become part of the standard of care. We project a FY2019 launch, and that IMMU-132 will achieve $720MM in worldwide revenue in mTNBC by 2025."

FY 2017 EPS estimate is for a loss of $1.10 and FY 2018 EPS estimate is for a loss of $0.70.

For an analyst ratings summary and ratings history on Immunomedics click here. For more ratings news on Immunomedics click here.

Shares of Immunomedics closed at $7.47 yesterday.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up